TTPH Tetraphase Pharmaceuticals Inc.

4.58
-0.49  -10%
Previous Close 5.07
Open 5.07
Price To Book 0.3
Market Cap 12,438,483
Shares 2,715,826
Volume 106,316
Short Ratio
Av. Daily Volume 74,420
Stock charts supplied by TradingView

NewsSee all news

  1. Tetraphase Pharmaceuticals Announces Reverse Stock Split

    Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections,

  2. Tetraphase Pharmaceuticals to Present XERAVA™ (Eravacycline) Data at IDWeek 2019

    – Seven Abstracts Selected for Poster Presentations – Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA™ (eravacycline for injection)

  3. Tetraphase Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

    Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections, today

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial did not meet endpoints September 2015. Additional Phase 3 trial also did not meet primary endpoints - noted February 13, 2018.
Eravacycline (TP-434) - IGNITE3
cUTI - complicated urinary tract infections
FDA approval announced August 27, 2018.
Eravacycline (TP-434) - IGNITE4
cIAI (complicated intra-abdominal infections)
Phase 1 trial complete.
TP-271
Community-acquired bacterial pneumonia (CABP)
Phase 2 ready.
TP-6076

Latest News

  1. Tetraphase Pharmaceuticals Announces Reverse Stock Split

    Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections,

  2. Tetraphase Pharmaceuticals to Present XERAVA™ (Eravacycline) Data at IDWeek 2019

    – Seven Abstracts Selected for Poster Presentations – Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVA™ (eravacycline for injection)

  3. Tetraphase Pharmaceuticals to Present at the H.C. Wainwright Global Investment Conference

    Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on commercializing its novel tetracycline XERAVATM (eravacycline for injection) to treat serious and life-threatening infections, today